Vernalis PLC

Promising Results of Ph Ib/II POC Study in ADHD - Seite 2

 -- ends --

Enquiries:
Vernalis plc:
Ian Garland, Chief Executive Officer	[phone]
David Mackney, Chief Financial Officer
Canaccord Genuity Limited (Nominated Adviser):	[phone]
Lucy Tilley
Dr Julian Feneley
Henry Fitzgerald-O'Connor
Shore Capital (Joint Broker):	[phone]
Bidhi Bhoma
Toby Gibbs
Brunswick Group:	[phone]
Jon Coles

Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.